Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Long-Term Extension in Early RA
NCT01668966Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2013
- Primary completion
- May 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 104 weeks, Percentage of Participants With TEAEs of Special Interest at 104 weeks and 1 more. Started Dec 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01668966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668966.